- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07613593
INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease (INCLUDE-CKD)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
- Retrospective: ~450-500 existing users + matched controls(24 months data).
- Comparison with entire WKC CKD population
- Prospective: ~500-550 new users + matched controls (6 months).
- Exploratory: ~500 dialysis or pre transplant MyRenalCare users (no matched controls).
- Qualitative: 15-25 patients + 10-15 staff.
La description
Inclusion Criteria:
5.1.1 Inclusion criteria - MyRenalCare users (retrospective and prospective cohorts)
Adults will be eligible for inclusion in the MyRenalCare cohorts if they meet all of the following:
- Aged 18 years or over.
- Under the care of the Wessex Kidney Centre
- Registered with, or offered and subsequently enrolled onto, the MyRenalCare platform during the defined retrospective or prospective periods.
- Able to understand study information and, where applicable, provide informed consent for use of their data for research purposes.
Specific CKD stage definitions and thresholds (e.g. based on eGFR, albuminuria or uPCR) will be documented in the study manual to ensure consistent application.
5.1.2 Inclusion criteria - matched usual care controls
Adults will be eligible for inclusion in the matched control cohorts if they meet all of the following:
- Aged 18 years or over.
- Under the care of the Wessex Kidney Centre for chronic kidney disease.
- Not registered with or using MyRenalCare at any point during the relevant observation period.
- Have sufficient clinical and administrative data available in the renal electronic patient record to enable matching and outcome assessment.
Controls will be identified retrospectively from the renal electronic patient record and matched to MyRenalCare users using a predefined matching strategy.
5.1.3 Inclusion criteria - qualitative interview participants (patients and staff)
Patients will be eligible to take part in the qualitative interview component if they meet all of the following:
- Aged 18 years or over.
- Currently using, or recently offered, the MyRenalCare platform as part of their CKD care at the Wessex Kidney Centre.
- Able to understand spoken and written English to the extent required for participation in an interview.
- Able and willing to provide written informed consent for participation in a recorded interview.
- Belong to a demographic or clinical subgroup of interest for the study (e.g. varying age, ethnicity, CKD stage, or digital engagement level), as part of purposive sampling to support diversity and equity analysis.
Clinical staff will be eligible if they meet all of the following:
- Employed by PHU or working in direct partnership with the Wessex Kidney Centre.
- Directly involved in the care of patients with chronic kidney disease and/or in the implementation or support of MyRenalCare.
- Able and willing to provide informed consent for a recorded interview.
- Able to reflect on experiences and observations relevant to the delivery, uptake, or equity implications of digital health in CKD.
Exclusion Criteria:
- Patients with acute kidney injury without established chronic kidney disease.
- Patients with a very limited life expectancy where participation in routine digital monitoring is not appropriate, as judged by the clinical team.
- Patients who have previously indicated that they do not wish their routinely collected clinical data to be used for research where such opt-out applies to this study.
- Patients who are unable to be identified reliably in the available data sources (for example, inconsistent or missing key identifiers).
- Any other situation where, in the opinion of the responsible clinician, participation in the study processes (including data use) would be inappropriate or unduly burdensome.
- Clinical staff who are not directly involved in the care of patients with chronic kidney disease or in the implementation of the MyRenalCare platform.
- Staff members currently on extended leave or unable to participate during the data collection period.
- Individuals who do not wish to have their views included in recorded interview transcripts or are unable to provide informed consent for participation.
- Any situation where, in the opinion of the study team or the individual's manager, participation would be inappropriate or burdensome due to role, availability, or conflict of interest.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Existing MyRenalCare users (retrospective cohort)
Adults who were already registered and actively using MyRenalCare at the start of the retrospective observation period.
Data will be collected retrospectively from their routine use of the platform.
|
Study is non-interventional.
Autres noms:
|
|
New MyRenalCare users (prospective cohort)
Adults who are newly offered and enroll onto MyRenalCare during the defined recruitment window.
Participants will use the platform as part of routine care, and their engagement will be prospectively monitored.
|
Study is non-interventional.
Autres noms:
|
|
Matched usual care controls
Adults with CKD receiving standard care at the Wessex Kidney Centre who are not enrolled onto MyRenalCare.
These participants receive usual clinical care without access to the MyRenalCare platform.
|
Study is non-interventional.
Autres noms:
|
|
Patients and staff participating in qualitative interviews (qualitative cohort)
A subset of MyRenalCare users (both retrospective and prospective) and clinical staff involved in their care who are invited to take part in interviews about their experiences with MyRenalCare.
|
Study is non-interventional.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Primary
Délai: 12 months
|
Outcome measure 1: Number and proportion of MyRenalCare users by age, sex, ethnicity and Index of Multiple Deprivation quintile, compared with the CKD population under Wessex Kidney Centre care.
Prevalence ratios will also be calculated.
|
12 months
|
|
Primary
Délai: 12-months
|
Outcome measure 2: Composite digital adherence score (0-100) for MyRenalCare users, combining log-in frequency, completeness of blood pressure and symptom entries, use of secure messaging and duration of sustained use. Analyses stratified by age, sex, ethnicity and deprivation. |
12-months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Secondary
Délai: 12-months
|
Outcome measure1: Number of unplanned and planned hospital admissions for MyRenalCare users compared with matched usual-care controls.
|
12-months
|
|
Secondary
Délai: 12-months
|
Outcome measure 2: Number of outpatient visits (renal and non-renal) for MyRenalCare users compared with matched usual-care controls.
|
12-months
|
|
Secondary
Délai: 12-months
|
Outcome measure 3: CKD progression, measured by change in eGFR, movement between CKD stages, and initiation of kidney replacement therapy for MyRenalCare users versus matched controls.
|
12-months
|
|
Secondary
Délai: 12-months
|
Outcome measure 4: NHS healthcare costs per patient-year for MyRenalCare users compared with matched usual-care controls, including inpatient, outpatient, emergency and relevant community or virtual care contacts.
|
12-months
|
|
Secondary
Délai: 12-months
|
Outcome measure 5: Estimated patient travel-related CO₂ emissions for renal care appointments for MyRenalCare users versus matched usual-care controls, based on travel distance and mode.
|
12-months
|
|
Secondary
Délai: 12-months
|
Outcome measure 6: Themes from qualitative interviews with patients and staff on MyRenalCare usability, support needs, barriers and facilitators to digital engagement.
|
12-months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Processus pathologiques
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladie chronique
- Attributs de la maladie
- Insuffisance rénale
- Conditions pathologiques, signes et symptômes
- Insuffisance rénale chronique
Autres numéros d'identification d'étude
- PHU/2024/28
- NIHR510403 (Autre identifiant: NIHR - 2025/400 i4i FAST Commissioned)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Maladie rénale chronique
-
Zhen LiInscription sur invitationTransplantation simultanée Pancreas-KidneyChine
-
University Hospital, Basel, SwitzerlandPas encore de recrutementSyndrome cardiovasculaire-kidney-métabolique | Cradiovascular-Kidney-Liver-Metabolic (CKLM) SyndromeSuisse
-
Chung Shan Medical UniversityNational Science and Technology Council, TaiwanPas encore de recrutementObésité Diabète de type 2 | Maladie hépatique stéatosique associée à un dysfonctionnement métabolique | Syndrome cardiovasculaire-kidney-métaboliqueTaïwan
-
CHU de ReimsPas encore de recrutementRéactivité des fluides au début de la période de transplantation après le kidneyFrance
-
Camille N. Kotton, MDKamada, Ltd.; University of Texas Southwestern Medical CenterRecrutementCytomégalovirus | Greffe du rein; Complications | Greffe d'organe | Complantation du foie | Transplantation simultanée du foie-kidney; ComplicationsÉtats-Unis
-
Nanjing Medical UniversityPas encore de recrutementSyndrome cardiovasculaire-kidney-métabolique
-
PfizerComplétéLeucémie, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) PositifFrance, États-Unis, Canada, Espagne, Tchéquie, Singapour, Thaïlande, Danemark, Norvège, Corée, République de, Finlande, Hongrie, Suède, Pays-Bas, Italie, Allemagne, Ukraine, Afrique du Sud, Taïwan, Australie, Belgique, Israël, Mexique, Pologn... et plus
-
First Affiliated Hospital of Fujian Medical UniversityRecrutementMaladies métaboliques | Maladie rénale chronique | Maladies cardiovasculaires (MCV) | Syndrome cardiovasculaire-kidney-métaboliqueChine
-
Chung Shan Medical UniversityNational Science and Technology Council, TaiwanComplétéDiabète de type 2 | Maladie du rein | Obésité et surpoids | Facteur de risque de maladie cardiovasculaire | Syndrome cardiovasculaire-kidney-métabolique
-
University of Alabama at BirminghamOhio State University; American Heart Association; Tuskegee UniversityRecrutementMaladies cardiovasculaires | Fumeur | Hypertension | Obésité | Diabète | Hyperlipidémie | Maladie du rein | Syndrome cardiovasculaire-kidney-métaboliqueÉtats-Unis
Essais cliniques sur Non-Interventional Study
-
Apple Inc.Stanford UniversityComplétéFibrillation auriculaire | Arythmies cardiaques | Flutter auriculaireÉtats-Unis
-
Radicle ScienceComplétéLa dépression | La douleur | Dormir | AnxiétéÉtats-Unis
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCActif, ne recrute pasMaladies du cerveau | Maladies du système nerveux central | Maladies du système nerveux | Maladie de Parkinson | Troubles parkinsoniens | Maladies des noyaux gris centraux | Troubles du mouvement | Maladies neurodégénérativesPays-Bas
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCComplétéMaladies du cerveau | Troubles du mouvement | Maladies neurodégénératives | Paralysie supranucléaire progressivePays-Bas
-
Radicle ScienceComplété
-
Radicle ScienceComplété
-
Radicle ScienceComplété
-
Digisight Technologies, Inc.InconnueLa rétinopathie diabétique | Dégénérescence maculaire liée à l'âge | MétamorphopsieÉtats-Unis
-
Radicle ScienceComplétéFonction sexuelle | Satisfaction sexuelleÉtats-Unis
-
St. Joseph's Healthcare HamiltonSuspendu